Evolus Q4 2025 slides: revenue growth continues despite forecast miss

Evolus Inc. (NASDAQ:EOLS) presented its fourth quarter 2025 results on March 3, 2026, reporting continued revenue growth but falling slightly short of analyst expectations, triggering a nearly 4% aftermarket stock decline. The aesthetics company’s investor presentation highlighted significant strategic progress in its transformation from a single-product neurotoxin provider to a diversified aesthetics portfolio company, even as near-term performance challenges weighed on market sentiment.